In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

ASX Announcements

The Company publishes all ASX Announcements below.  Previous years can be found under the archives at the bottom of the page.

2018

Date Announcement
04/10/2018

European Society for Medical Oncology President joins Imugene Scientific Advisory Board

01/10/2018

Imugene appoints leading cancer researcher to Scientific Advisory Board

21/09/2018

 

Imugene commences cGMP manufacture of PD-1 cancer vaccine

18/09/2018

Imugene appoints gastrointestinal cancer expert to Scientific

Advisory Board

11/09/2018

Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

23/08/2018

Imugene appoints Dr Mark Marino Chief Medical Officer

27/07/2018

2018 Bioshares Presentation

23/07/2018

PD-1 cancer vaccine development update

07/06/2018

Capital Raising Presentation

07/06/2018

Prospectus

07/06/2018

Imugene to Raise A$20.1 million

07/06/2018

Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio

05/06/2018

Trading Halt

28/03/2018

Leslie Chong Appointed as Managing Director

18/02/2018

Imugene arginine modulator demonstrates activity in melanoma cancer model

11/02/2018

Novel Anti-PD-1 Mimotope Vaccine Ready for Development

09/02/2018

Imugene hosts investigator meeting for gastric cancer clinical trial

07/02/2018

Cancer vaccine shows early promise in gastric cancer clinical trial

29/01/2018

Business Update – December Quarter Appendix 4C

2016

Date Announcement
19/12/2016

Imugene progresses mimotope platform with filing of new patents

13/12/2016

Imugene acquires immuno-oncology technology from Baker IDI

02/12/2016

New Imugene Investor Presentation

21/11/2016

Leslie Chong Appointed Chief Executive Officer

06/11/2016

Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study

21/10/2016

Imugene Share Placement raises $3.2 million

30/09/2016

Notice of Annual General Meeting

20/09/2016

Imugene successfully completes preclinical animal studies

30/08/2016

Imugene’s Final Cancer Vaccine Doses Delivered to GMP Depot in Singapore

22/08/2016

Imugene Receives Approval from Thailand to Start Gastric Cancer Study

11/08/2016

Imugene Receives IRB approval from the Taipei Veterans General Hospital

29/07/2016

Appendix 4C - Quaterly

11/07/2016

Imugene Receives Institutional Review Board approval from the University of Hong Kong

30/05/2016

Imugene Completes Submission to Hospital Ethics Committees for HER-Vaxx

21/04/2016

Imugene submits regulatory package for HER-Vaxx Phase 1b/2 study in gastric cancer

13/04/2016

Imugene Shareholder Newsletter and Update

12/04/2016

Imugene appoints Dr. Yelena Janjigian as a Scientific Advisory Board member

08/03/2016

Manufacturing Update: on track and below budget

10/02/2016

Imugene to present at the RedChip Global Online Microcap Conference

20/01/2016

Partnership to Develop Mimotope Immuno-Oncology Platform

15/01/2016

Imugene to present at Noble Financial Capital Markets’ 12th Annual Investor Conference

11/01/2016

Biotech Showcase Presentation by Leslie Chong

05/01/2016

Imugene names Dr. Anton Uvarov as new Non-Executive Director

04/01/2016

Imugene names Stuart Roberts as Head of Corporate Development

Archive

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551